Table 1.

Characteristics of patients undergoing ASCT

Patients’ characteristics	Overall (n = 136)	LEVO-group (n = 38)	NO-LEVO-group (n = 98)	P value
Baseline
Age at ASCT, y, median (IQR)	59 (52-66)	63 (50-66)	58 (52-65)	.86
Male sex	87 (64%)	24 (63.2%)	63 (64.3%)	.90
Total number of ASCT for patient				.66
First ASCT	104 (76.5%)	30 (78.9%)	74 (75.5%)
Second ASCT	30 (22%)	8 (21.1%)	22 (22.5%)
Third ASCT	2 (1.5%)	0 (0%)	2 (2%)
Diagnosis				.82
Myeloid disorders	4 (2.9%)	1 (2.6%)	3 (3.1%)
Lymphoid disorders	127 (93.4%)	35 (92.1%)	92 (93.8%)
Other disorders	5 (3.7%)	2 (5.3%)	3 (3.1%)
Disease status at ASCT				.46
Complete response	86 (63.2%)	21 (55.2%)	65 (66.3%)
Active disease	45 (33.1%)	15 (39.5%)	30 (30.6%)
Other	5 (3.7%)	2 (5.3%)	3 (3.1%)
Ongoing line of therapy				.75
First line	104 (76.5%)	29 (76.3%)	75 (76.5%)
Second line	21 (15.4%)	5 (13.2%)	16 (16.3%)
Third line	11 (8.1%)	4 (10.5%)	7 (7.2%)
Conditioning chemotherapy				.75
Myeloablative	120 (88.2%)	33 (86.8%)	87 (88.8%)
Reduced intensity	16 (11.8%)	5 (13.2%)	11 (11.2%)
ANC <500 cells/mm3 ≥ 7 d	0 (0%)	0 (0%)	0 (0%)	-
MDR-GNB rectal carrier ≤30 d before ASCT	1 (0.7%)	0 (0%)	1 (1%)	.53
Antibiotics ≤90 d before ASCT	12 (8.8%)	0 (0%)	12 (12.2%)	.02
Follow-up
Follow-up, d, median (IQR)	318 (153-596)	758 (188-964)	256 (149-523)	.0001
ANC engraftment	136 (100%)	38 (100%)	98 (100%)	-
Time to engraftment, d, median (IQR)	11 (10-11.5)	11 (10-11)	11 (10-12)	.82
Relapse	22 (16.2%)	10 (26.3%)	12 (12.2%)	.05
Overall death	13 (9.6%)	7 (18.4%)	6 (6.1%)	.03
Causes of death				.13
Disease	8 (5.9%)	5 (13.2%)	3 (3.1%)
IRM	3 (2.2%)	1 (2.6%)	2 (2%)
Others	2 (1.5%)	1 (2.6%)	1 (1%)